Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pathology

Symptoms, Pathology & Diagnosis

At a Glance

Castleman disease is diagnosed using an excisional biopsy to examine the entire lymph node structure, which distinguishes it from conditions like lymphoma. A definitive diagnosis requires identifying specific cellular patterns and ruling out infections like HHV-8.

Understanding how Castleman disease (CD) is diagnosed is the first step in taking control of your care. Because CD is a “mimic”—appearing very similar to other conditions—doctors must follow a rigorous, step-by-step process to ensure an accurate diagnosis [1][2].

The Gold Standard: Excisional Biopsy

When it comes to diagnosing Castleman disease, the method of biopsy matters deeply.

  • Why Excisional is Essential: An excisional biopsy (removing the entire lymph node) is strongly preferred over a fine needle aspiration (FNA) or core needle biopsy [3][4].
  • The Big Picture: CD is diagnosed by looking at the “architecture” or the overall pattern of the lymph node. A needle only takes a tiny “core” or a few cells, which may not show the full pattern. An excisional biopsy allows the pathologist to see the entire structure, which is critical to distinguish CD from lymphoma [3][5].

Deciphering Your Pathology Report

Your pathology report might contain technical terms that describe what the cells look like under a microscope. These are the “variants” of Castleman disease:

  • Hyaline Vascular (HV): Often seen in Unicentric CD, this shows many small blood vessels (vascular) and thickened, “glassy” connective tissue (hyaline) [6][7].
  • Plasmacytic (Plasma Cell): Often seen in Multicentric CD, this shows large “sheets” of plasma cells (immune cells that make antibodies) [8][9].
  • Mixed Variant: A combination of both the vascular and plasma cell patterns [7].
  • Polytypic Plasmacytosis: This term means you have many different types of plasma cells (polytypic), which is a sign of a reactive immune response (like CD) rather than a cancer where all cells are identical (monotypic) [8][10].

The Diagnostic Checklist for iMCD

For Idiopathic Multicentric Castleman Disease (iMCD), the Castleman Disease Collaborative Network (CDCN) established strict criteria. You generally need both major criteria and at least two minor criteria (including one lab result) [1][11].

Criteria Category Requirements
Major Criteria 1. Characteristic lymph node pathology AND 2. Enlarged lymph nodes in multiple regions [1].
Minor (Laboratory) Elevated CRP, anemia, low albumin, renal dysfunction, or high antibody levels (polyclonal hypergammaglobulinemia) [1][12].
Minor (Clinical) Enlarged liver/spleen (hepatosplenomegaly), fluid buildup (edema), or “flu-like” constitutional symptoms [1].

Ruling Out the “Mimics”

A diagnosis of iMCD is only official after a doctor has “excluded” or ruled out other diseases that look the same. This is why you may have undergone many tests for:

  • Infections: HIV and HHV-8 (Human Herpesvirus-8) must be tested. If you test positive for HHV-8, you still have Castleman disease, but you are diagnosed with the HHV-8 Associated MCD subtype rather than the ‘idiopathic’ (iMCD) form [13][14].
  • Cancer: Lymphoma and plasma cell cancers must be excluded [15][16].
  • Autoimmune: Conditions like Systemic Lupus Erythematosus (SLE) or IgG4-related disease can mimic the symptoms of CD [17][18].

Completeness Checklist for Your Records

Ensure your medical folder includes these specific items to confirm a thorough diagnostic workup:

  • [ ] Full Pathology Report from an excisional biopsy (not just a needle biopsy) [3].
  • [ ] HHV-8 Status: Often listed as “LANA-1 negative” on the pathology report [13].
  • [ ] Imaging Results: A PET/CT or CT scan showing if nodes are in one area (UCD) or many (MCD) [19].
  • [ ] Blood Work: Specifically checking for high CRP (inflammation marker), low hemoglobin (anemia), and low albumin [12][20].
  • [ ] HIV Test: To confirm the disease is “idiopathic” and not caused by an underlying infection [21].

Common questions in this guide

Why do I need an excisional biopsy instead of a needle biopsy for Castleman disease?
An excisional biopsy removes the entire lymph node, allowing the pathologist to see its complete structure. This full view is essential to accurately diagnose Castleman disease and distinguish it from similar conditions like lymphoma, which a smaller needle biopsy might miss.
What does "hyaline vascular" mean on my pathology report?
The hyaline vascular variant is a specific pattern seen under the microscope, usually in Unicentric Castleman disease. It means your lymph node has many small blood vessels and thickened, glassy-looking connective tissue.
How is idiopathic multicentric Castleman disease (iMCD) officially diagnosed?
Doctors use a specific checklist of criteria to diagnose iMCD. You generally need to have characteristic lymph node changes, enlarged nodes in multiple areas, and at least two minor criteria like specific abnormal lab results or clinical symptoms.
Why does my doctor need to test for HIV and HHV-8?
Certain viruses like HIV and Human Herpesvirus-8 (HHV-8) can cause enlarged lymph nodes that look identical to Castleman disease. Testing for these viruses helps your doctor determine if you have a virus-associated subtype or the idiopathic form of the disease.
What blood tests are important for diagnosing Castleman disease?
Key blood tests include checking for high C-reactive protein (a marker of inflammation), low hemoglobin (anemia), and low albumin levels. These tests help your doctor confirm if you meet the minor diagnostic criteria for multicentric Castleman disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why did you choose this specific biopsy method (excisional vs. needle), and is the sample large enough to see the full architecture of the lymph node?
  2. 2.Have we definitively ruled out 'mimics' like lymphoma, HIV, and autoimmune diseases? Which specific tests confirmed this?
  3. 3.My pathology report mentions a specific variant—how does this type influence my treatment plan?
  4. 4.Do I meet the CDCN major and minor criteria for iMCD, and which specific minor criteria did I meet?
  5. 5.Was my tissue sample stained for HHV-8 (LANA-1), and what were the results?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

    Fajgenbaum DC, Uldrick TS, Bagg A, et al.

    Blood 2017; (129(12)):1646-1657 doi:10.1182/blood-2016-10-746933.

    PMID: 28087540
  2. 2

    Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy.

    Nijim S, Fajgenbaum DC

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):582-593 doi:10.1182/hematology.2024000582.

    PMID: 39644038
  3. 3

    Comparative analysis on efficacy of lymph node sampling through whole node excision versus core needle biopsy: focusing on diagnostic yield for interpretation.

    Singh N, Mishra S, Balasubramanian P, et al.

    Journal of hematopathology 2025; (18(1)):46 doi:10.1007/s12308-025-00662-6.

    PMID: 41087604
  4. 4

    An economic evaluation of fine-needle cytology as the primary diagnostic tool in the diagnosis of lymphadenopathy.

    Cavallo M, Ciliberti V, Maffei E, et al.

    Open medicine (Warsaw, Poland) 2023; (18(1)):20230719 doi:10.1515/med-2023-0719.

    PMID: 37305522
  5. 5

    Image-guided lymph node fine-needle aspiration: the Johns Hopkins Hospital experience.

    Shyu S, Rajgariah A, Saoud C, et al.

    Journal of the American Society of Cytopathology 2021; (10(6)):543-557 doi:10.1016/j.jasc.2021.04.004.

    PMID: 34088642
  6. 6

    Cutaneous manifestations of Castleman disease.

    Chavez-Alvarez S, Villarreal-Martinez A, Ocampo-Candiani J, et al.

    International journal of dermatology 2020; (59(10)):1226-1240 doi:10.1111/ijd.15043.

    PMID: 32686150
  7. 7

    Castleman Disease: A Rare Condition with Endocrine Manifestations.

    Cervantes CE, Correa R

    Cureus 2015; (7(11)):e380 doi:10.7759/cureus.380.

    PMID: 26719823
  8. 8

    Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease.

    Shiroshita K, Kikuchi T, Okayama M, et al.

    Internal medicine (Tokyo, Japan) 2020; (59(23)):3061-3065 doi:10.2169/internalmedicine.5046-20.

    PMID: 32759587
  9. 9

    A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features.

    Igawa T, Omote R, Sato H, et al.

    Pathology, research and practice 2017; (213(11)):1378-1383 doi:10.1016/j.prp.2017.09.015.

    PMID: 28974340
  10. 10

    Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome.

    Rodriguez-Merino L, Montes-Moreno S

    Annals of diagnostic pathology 2025; (74()):152414 doi:10.1016/j.anndiagpath.2024.152414.

    PMID: 39608292
  11. 11

    Title not available

    Bertinchamp R, Terriou L

    La Revue de medecine interne 2022; (43(10S1)):10S4-10S9 doi:10.1016/S0248-8663(23)00019-X.

    PMID: 36657941
  12. 12

    Idiopathic multicentric Castleman disease.

    Chaudhari V, Thakkar SJ, Padwal N, Karnik N

    Journal of cancer research and therapeutics 2024; (20(5)):1602-1604 doi:10.4103/jcrt.jcrt_2190_22.

    PMID: 39412927
  13. 13

    Idiopathic multicentric Castleman disease in an adolescent diagnosed following COVID-19 infection.

    Mosleh E, Mehta S, Young E, et al.

    Pediatric blood & cancer 2023; (70(6)):e30239 doi:10.1002/pbc.30239.

    PMID: 36720636
  14. 14

    Castleman disease: A single-center case series.

    Pribyl K, Vakayil V, Farooqi N, et al.

    International journal of surgery case reports 2021; (80()):105650 doi:10.1016/j.ijscr.2021.105650.

    PMID: 33631648
  15. 15

    Peculiar hyper vascular manifestations in idiopathic multicentric castleman disease without tafro syndrome: a case report.

    Jilani RK, Saleem MR, Akhtar S, Jawad W

    Annals of hematology 2024; (103(12)):5929-5934 doi:10.1007/s00277-024-06040-z.

    PMID: 39400742
  16. 16

    Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated lymphoproliferative disorders.

    Oksenhendler E, Boutboul D, Galicier L

    Blood 2019; (133(11)):1186-1190 doi:10.1182/blood-2018-11-852442.

    PMID: 30610029
  17. 17

    Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.

    Otani K, Inoue D, Fujikura K, et al.

    Oncotarget 2018; (9(6)):6691-6706 doi:10.18632/oncotarget.24068.

    PMID: 29467920
  18. 18

    Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma.

    Gunathilake K, Rifath M, Munasinghe BM, et al.

    SAGE open medical case reports 2022; (10()):2050313X221106110 doi:10.1177/2050313X221106110.

    PMID: 36388638
  19. 19

    Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

    Koa B, Borja AJ, Aly M, et al.

    Insights into imaging 2021; (12(1)):35 doi:10.1186/s13244-021-00963-1.

    PMID: 33709329
  20. 20

    Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.

    Mumau MD, Gonzalez MV, Forsyth KS, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.64898/2025.12.12.693846.

    PMID: 41446181
  21. 21

    HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.

    Chadburn A, Said J, Gratzinger D, et al.

    American journal of clinical pathology 2017; (147(2)):171-187 doi:10.1093/ajcp/aqw218.

    PMID: 28395104

This page explains Castleman disease diagnostic criteria and pathology terminology for educational purposes. Your doctor and pathologist are the best sources for interpreting your specific biopsy results and establishing an official diagnosis.

Get notified when new evidence is published on Castleman disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.